首页 > 最新文献

Arquivos brasileiros de endocrinologia e metabologia最新文献

英文 中文
Maturity onset diabetes of young type 2 due to a novel de novo GKC mutation. 由一种新的新生GKC突变引起的年轻2型糖尿病的成熟发病。
Pub Date : 2014-10-01 DOI: 10.1590/0004-2730000003147
Paula Afonso, Nélia Ferraria, Alexandre Carvalho, Sofia Vidal Castro

Maturity Onset Diabetes of Young (MODY) is a heterogeneous group of monogenic disorders that result in β-cell dysfunction, with an estimated prevalence of 1%-2% in industrialized countries. MODY generally occurs in non-obese patients with negative autoantibodies presenting with mild to moderate hyperglycemia. The clinical features of the patients are heterogeneous, depending on the different genetic subtypes. We pretend to report a case of MODY type 2 caused by a novel de novo CGK mutation, highlighting the importance of the differential diagnosis in pediatric diabetes. A 13-year-old, healthy and non-obese girl was admitted for investigation of recurrent hyperglycemia episodes. She presented with persistent high levels of fasting blood glycemia (> 11.1 mmol/L) and had no familial history of diabetes. The blood glucose profile revealed an impaired fasting glucose of 124 mg/dL (6,9 mmol/L) with a normal oral glucose tolerance test. Fasting insulinemia was 15 mg/dL (90.1 pmol/L), HOMA-IR was 3.9 and hemoglobin A1c was 7.1%. Pancreatic autoantibodies were negative. Genetic testing identified a novel missense heterozygous mutation in exon 5 of GCK gene c.509G > T (p.Gly170Val), not present on the parents. This result established the diagnosis of MODY type 2. Clinical identification of patients with MODY remains a diagnostic challenge, especially when familial history is absent. Molecular diagnosis is very important for establishing an individualized treatment and providing a long term prognosis for each type of MODY.

青年成熟期发病糖尿病(MODY)是一组异质性单基因疾病,导致β细胞功能障碍,在工业化国家估计患病率为1%-2%。MODY通常发生在自身抗体阴性的非肥胖患者,伴有轻度至中度高血糖。患者的临床特征是异质的,取决于不同的遗传亚型。我们假装报告一个由新的新生CGK突变引起的2型MODY病例,强调小儿糖尿病鉴别诊断的重要性。一名13岁健康非肥胖女孩入院接受反复高血糖发作的调查。患者表现为持续高水平的空腹血糖(> 11.1 mmol/L),无糖尿病家族史。血糖谱显示空腹血糖为124 mg/dL (6,9 mmol/L),口服葡萄糖耐量试验正常。空腹胰岛素血症为15 mg/dL (90.1 pmol/L), HOMA-IR为3.9,血红蛋白A1c为7.1%。胰腺自身抗体为阴性。基因检测发现GCK基因c.509G > T (p.Gly170Val)外显子5有一个新的错义杂合突变,在亲本中不存在。该结果确立了MODY 2型的诊断。MODY患者的临床鉴定仍然是一个诊断挑战,特别是在没有家族病史的情况下。分子诊断对于建立个体化治疗和提供各种类型MODY的长期预后非常重要。
{"title":"Maturity onset diabetes of young type 2 due to a novel de novo GKC mutation.","authors":"Paula Afonso,&nbsp;Nélia Ferraria,&nbsp;Alexandre Carvalho,&nbsp;Sofia Vidal Castro","doi":"10.1590/0004-2730000003147","DOIUrl":"https://doi.org/10.1590/0004-2730000003147","url":null,"abstract":"<p><p>Maturity Onset Diabetes of Young (MODY) is a heterogeneous group of monogenic disorders that result in β-cell dysfunction, with an estimated prevalence of 1%-2% in industrialized countries. MODY generally occurs in non-obese patients with negative autoantibodies presenting with mild to moderate hyperglycemia. The clinical features of the patients are heterogeneous, depending on the different genetic subtypes. We pretend to report a case of MODY type 2 caused by a novel de novo CGK mutation, highlighting the importance of the differential diagnosis in pediatric diabetes. A 13-year-old, healthy and non-obese girl was admitted for investigation of recurrent hyperglycemia episodes. She presented with persistent high levels of fasting blood glycemia (> 11.1 mmol/L) and had no familial history of diabetes. The blood glucose profile revealed an impaired fasting glucose of 124 mg/dL (6,9 mmol/L) with a normal oral glucose tolerance test. Fasting insulinemia was 15 mg/dL (90.1 pmol/L), HOMA-IR was 3.9 and hemoglobin A1c was 7.1%. Pancreatic autoantibodies were negative. Genetic testing identified a novel missense heterozygous mutation in exon 5 of GCK gene c.509G > T (p.Gly170Val), not present on the parents. This result established the diagnosis of MODY type 2. Clinical identification of patients with MODY remains a diagnostic challenge, especially when familial history is absent. Molecular diagnosis is very important for establishing an individualized treatment and providing a long term prognosis for each type of MODY.</p>","PeriodicalId":8395,"journal":{"name":"Arquivos brasileiros de endocrinologia e metabologia","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2014-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1590/0004-2730000003147","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32793745","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
[Evaluation of fructosamine as a parameter of blood glucose control in diabetic pregnant women]. [果糖胺作为糖尿病孕妇血糖控制参数的评价]。
Pub Date : 2014-10-01 DOI: 10.1590/0004-2730000002990
Alina Coutinho Rodrigues Feitosa, Flávio Silva Andrade

Objective: To evaluate the alternative parameters to monitor glycemia in pregnant women with diabetes studying the relationship between fructosamine testing and self monitoring of blood glucose in pregnant women with diabetes.

Materials and methods: Serum fructosamine levels and the self monitoring of blood glucose over 14 days before the collection of fructosamine were evaluated in 47 diabetic pregnant women.

Results: Seventy-one fructosamine levels and 2,238 glucose measurements (CGs) were analysed. Levels of fructosamine correlated with high blood glucose index (HBGI) and the standard deviation of glycemias (r = 0.28; p = 0.021 and r = 0.26; p = 0.03, respectively). The comparison between the mothers of the newborns with appropriated or large birthweight and those who gave birth to small newborns for their gestational age (SGA) showed that the latter had a lower glycemic mean (105 vs. 114 and 119 mg/dL), a higher low blood glucose index (5.8 vs. 1.3 and 0.7) and a higher percentage of hyperglycemias (11 vs. 0 and 0%) even when the fructosamine falls within the reference values (242 vs. 218 and 213 μmol/l).

Conclusion: The levels of fructosamine can be used as further parameter to aid self monitoring of blood glucose to evaluate hyperglycemias and glycemic variability, however, this can underestimate hypoglycemias in pregnant women carrying small-for-gestational age fetuses.

目的:评价糖尿病孕妇血糖监测的替代参数,探讨果糖胺检测与糖尿病孕妇血糖自我监测的关系。材料与方法:对47例糖尿病孕妇采集果糖胺前14天的血清果糖胺水平及血糖自我监测进行评价。结果:分析了71例果糖胺水平和2238例葡萄糖测量(CGs)。果糖胺水平与高血糖指数(HBGI)和血糖标准差相关(r = 0.28;P = 0.021, r = 0.26;P = 0.03)。结果表明,即使果糖胺含量在参考值范围内(242 μmol/l vs 218 μmol/l和213 μmol/l),出生体重适中或较大新生儿的母亲与胎龄较小新生儿的母亲(SGA)的血糖平均值较低(105比114和119 mg/dL),低血糖指数较高(5.8比1.3和0.7),高血糖百分比较高(11比0和0%)。结论:果糖胺水平可以作为进一步的参数来帮助自我监测血糖,以评估高血糖和血糖变异性,但这可能低估了低血糖的孕妇携带小胎龄胎儿。
{"title":"[Evaluation of fructosamine as a parameter of blood glucose control in diabetic pregnant women].","authors":"Alina Coutinho Rodrigues Feitosa,&nbsp;Flávio Silva Andrade","doi":"10.1590/0004-2730000002990","DOIUrl":"https://doi.org/10.1590/0004-2730000002990","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the alternative parameters to monitor glycemia in pregnant women with diabetes studying the relationship between fructosamine testing and self monitoring of blood glucose in pregnant women with diabetes.</p><p><strong>Materials and methods: </strong>Serum fructosamine levels and the self monitoring of blood glucose over 14 days before the collection of fructosamine were evaluated in 47 diabetic pregnant women.</p><p><strong>Results: </strong>Seventy-one fructosamine levels and 2,238 glucose measurements (CGs) were analysed. Levels of fructosamine correlated with high blood glucose index (HBGI) and the standard deviation of glycemias (r = 0.28; p = 0.021 and r = 0.26; p = 0.03, respectively). The comparison between the mothers of the newborns with appropriated or large birthweight and those who gave birth to small newborns for their gestational age (SGA) showed that the latter had a lower glycemic mean (105 vs. 114 and 119 mg/dL), a higher low blood glucose index (5.8 vs. 1.3 and 0.7) and a higher percentage of hyperglycemias (11 vs. 0 and 0%) even when the fructosamine falls within the reference values (242 vs. 218 and 213 μmol/l).</p><p><strong>Conclusion: </strong>The levels of fructosamine can be used as further parameter to aid self monitoring of blood glucose to evaluate hyperglycemias and glycemic variability, however, this can underestimate hypoglycemias in pregnant women carrying small-for-gestational age fetuses.</p>","PeriodicalId":8395,"journal":{"name":"Arquivos brasileiros de endocrinologia e metabologia","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2014-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1590/0004-2730000002990","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32793765","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
A rare case of a parathyroid adenoma inside a parathyroid cyst. 甲状旁腺囊肿内甲状旁腺瘤的罕见病例。
Pub Date : 2014-10-01 DOI: 10.1590/0004-2730000003211
Spyridon N Karras, Ioannis Koutelidakis, Panagiotis Anagnostis, Gesthimani Mintziori, Nikolaos Pontikides, Dimitrios G Goulis

Parathyroid cysts (PCs) are rare lesions, located in the neck and anterior mediastinal region. The vast majority are non-functioning, presented as nodular cervical lesions. Large, non-functioning PCs can manifest with compressive symptoms of the surrounding tissues. Rarely, PCs produce excessive amounts of parathyroid hormone (PTH), resulting in primary hyperparathyroidism. We report a case of functional PC, describing its diagnostic and therapeutic approach.

甲状旁腺囊肿(PCs)是罕见的病变,位于颈部和前纵隔区。绝大多数是无功能的,表现为结节性宫颈病变。大的、无功能的pc可表现为周围组织的压迫症状。很少,pc产生过量的甲状旁腺激素(PTH),导致原发性甲状旁腺功能亢进。我们报告一例功能性PC,描述其诊断和治疗方法。
{"title":"A rare case of a parathyroid adenoma inside a parathyroid cyst.","authors":"Spyridon N Karras,&nbsp;Ioannis Koutelidakis,&nbsp;Panagiotis Anagnostis,&nbsp;Gesthimani Mintziori,&nbsp;Nikolaos Pontikides,&nbsp;Dimitrios G Goulis","doi":"10.1590/0004-2730000003211","DOIUrl":"https://doi.org/10.1590/0004-2730000003211","url":null,"abstract":"<p><p>Parathyroid cysts (PCs) are rare lesions, located in the neck and anterior mediastinal region. The vast majority are non-functioning, presented as nodular cervical lesions. Large, non-functioning PCs can manifest with compressive symptoms of the surrounding tissues. Rarely, PCs produce excessive amounts of parathyroid hormone (PTH), resulting in primary hyperparathyroidism. We report a case of functional PC, describing its diagnostic and therapeutic approach.</p>","PeriodicalId":8395,"journal":{"name":"Arquivos brasileiros de endocrinologia e metabologia","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2014-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1590/0004-2730000003211","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32793746","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 7
[Technical and functional aspects of catheterization of inferior petrosal sinuses in ACTH dependent Cushing's syndrome]. [ACTH依赖性库欣综合征岩下窦置管的技术和功能方面]。
Pub Date : 2014-10-01 DOI: 10.1590/0004-2730000003301
João Miguel de Almeida Silva, Guilherme Brasileiro de Aguiar, Mario Luiz Marques Conti, Américo Rubens Leite dos Santos, José Viana Lima Junior, José Carlos Esteves Veiga

Objective: To describe and analyze technique for bilateral catheterization of inferior petrosal sinus in our service, discussing the difficulties and success rates found.

Subjects and methods: Fourteen patients with suspected Cushing's syndrome underwent bilateral inferior petrosal sinuses (IPS) catheterization between 2009 and 2012. The technique for catheterization and for hormone analysis were described.

Results: The procedure was well tolerated by all patients, and adequate catheterization was achieved in 92.85% of cases. The diagnosis of Cushing's disease was confirmed in 10 cases. The result of IPS catheterization after CRH infusion was coherent in all cases, without false negatives.

Conclusion: The catheterization of IPS, despite being an invasive technique, is a safe procedure. The objectives can be done properly in most cases. When well indicated, this procedure remains the gold standard in distinguishing the ectopic form to pituitary source in Cushing's syndrome.

目的:介绍和分析双侧岩下窦置管技术,探讨其难点和成功率。对象和方法:2009年至2012年,14例疑似库欣综合征患者行双侧岩下窦(IPS)置管术。介绍了导管置管技术和激素分析技术。结果:所有患者耐受良好,92.85%的患者获得了适当的置管。10例确诊为库欣病。所有病例CRH输注后IPS置管结果一致,无假阴性。结论:IPS的导管导入术虽然是一种侵入性技术,但却是一种安全的手术。在大多数情况下,这些目标是可以正确实现的。当明确指示时,该手术仍然是区分库欣综合征异位形式与垂体源的金标准。
{"title":"[Technical and functional aspects of catheterization of inferior petrosal sinuses in ACTH dependent Cushing's syndrome].","authors":"João Miguel de Almeida Silva,&nbsp;Guilherme Brasileiro de Aguiar,&nbsp;Mario Luiz Marques Conti,&nbsp;Américo Rubens Leite dos Santos,&nbsp;José Viana Lima Junior,&nbsp;José Carlos Esteves Veiga","doi":"10.1590/0004-2730000003301","DOIUrl":"https://doi.org/10.1590/0004-2730000003301","url":null,"abstract":"<p><strong>Objective: </strong>To describe and analyze technique for bilateral catheterization of inferior petrosal sinus in our service, discussing the difficulties and success rates found.</p><p><strong>Subjects and methods: </strong>Fourteen patients with suspected Cushing's syndrome underwent bilateral inferior petrosal sinuses (IPS) catheterization between 2009 and 2012. The technique for catheterization and for hormone analysis were described.</p><p><strong>Results: </strong>The procedure was well tolerated by all patients, and adequate catheterization was achieved in 92.85% of cases. The diagnosis of Cushing's disease was confirmed in 10 cases. The result of IPS catheterization after CRH infusion was coherent in all cases, without false negatives.</p><p><strong>Conclusion: </strong>The catheterization of IPS, despite being an invasive technique, is a safe procedure. The objectives can be done properly in most cases. When well indicated, this procedure remains the gold standard in distinguishing the ectopic form to pituitary source in Cushing's syndrome.</p>","PeriodicalId":8395,"journal":{"name":"Arquivos brasileiros de endocrinologia e metabologia","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2014-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1590/0004-2730000003301","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32793770","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Zinc transporter 8 autoantibodies in patients with type 1 diabetes from a multiethnic population and their first degree relatives. 多民族人群及其一级亲属1型糖尿病患者锌转运蛋白8自身抗体的研究
Pub Date : 2014-10-01 DOI: 10.1590/0004-2730000003088
Débora Batista Araujo, Hanna Skärstrand, Bianca Barone, Joana Rodrigues Dantas, Rosane Kupfer, Lenita Zajdenverg, Adolpho Milech, Fariba Vaziri-Sani, José Egídio Paulo de Oliveira, Melanie Rodacki

Objective: Zinc transporter 8 autoantibodies (ZnT8A) have been poorly studied in non-Caucasian individuals. We aimed to investigate the prevalence of ZnT8 autoantibodies in patients with T1D and their first degree relatives (FDR) from a multiethnic population, as well as its relation with the insulin (INS) or the protein tyrosine phosphatase non-receptor 22 (PTPN22) gene polymorphisms.

Subjects and methods: ZnT8A were analyzed in sera from T1D patients (n = 72, mean age of 30.3 ± 11.4 years) of variable duration (15.7 ± 11.8 years) and their FDR (n = 78, mean age of 18.3 ± 9.1 years) by a triple mix Radioligand Binding Assay (RBA) for the ZnT8 autoantibody (ZnT8-RWQ) variants. SNP (single nucleotide polymorphism) for INS and PTPN22 were genotyped.

Results: The prevalence of ZnT8A was higher in T1D patients than FDR, for ZnT8TripleA (24% vs. 4%,p = 0.001), ZnT8RA (24% vs. 4%, p < 0.001) and ZnT8QA (15% vs. 3%, p = 0.004). All FDR with ZnT8A (n = 3) had at least another positive antibody. Heterozygosis for PTPN22 was associated with a higher frequency of ZnT8TripleA (p = 0.039) and ZnT8RA (p = 0.038).

Conclusions: ZnT8A is observed in non-Caucasian patients with T1D, even years after the disease onset, as well as in their FDR. In those, there was an overlap between ZnT8A and other T1D antibodies. ZnT8A was associated with PTPN22 polymorphisms. Further longitudinal studies are necessary to elucidate the importance of these findings in the natural history of T1D patients with multiethnic background.

目的:锌转运蛋白8自身抗体(ZnT8A)在非白种人中的研究很少。我们旨在调查来自多种族人群的T1D患者及其一级亲属(FDR)中ZnT8自身抗体的患病率,以及它与胰岛素(INS)或蛋白酪氨酸磷酸酶非受体22 (PTPN22)基因多态性的关系。研究对象和方法:采用三混合放射配体结合试验(RBA)对不同病程(15.7±11.8年)的T1D患者(n = 72,平均年龄30.3±11.4岁)及其FDR (n = 78,平均年龄18.3±9.1岁)的ZnT8自身抗体(ZnT8- rwq)变体进行ZnT8A分析。对INS和PTPN22的单核苷酸多态性进行基因分型。结果:T1D患者中ZnT8A的患病率高于FDR, ZnT8TripleA(24%比4%,p = 0.001)、ZnT8RA(24%比4%,p < 0.001)和ZnT8QA(15%比3%,p = 0.004)。所有携带ZnT8A的FDR (n = 3)至少有另一种抗体阳性。PTPN22的杂合子与ZnT8TripleA (p = 0.039)和ZnT8RA (p = 0.038)的高频率相关。结论:在非高加索T1D患者中观察到ZnT8A,甚至在疾病发病数年后,以及他们的FDR。在这些病例中,ZnT8A和其他T1D抗体之间存在重叠。ZnT8A与PTPN22多态性相关。需要进一步的纵向研究来阐明这些发现在多种族背景的T1D患者自然史中的重要性。
{"title":"Zinc transporter 8 autoantibodies in patients with type 1 diabetes from a multiethnic population and their first degree relatives.","authors":"Débora Batista Araujo,&nbsp;Hanna Skärstrand,&nbsp;Bianca Barone,&nbsp;Joana Rodrigues Dantas,&nbsp;Rosane Kupfer,&nbsp;Lenita Zajdenverg,&nbsp;Adolpho Milech,&nbsp;Fariba Vaziri-Sani,&nbsp;José Egídio Paulo de Oliveira,&nbsp;Melanie Rodacki","doi":"10.1590/0004-2730000003088","DOIUrl":"https://doi.org/10.1590/0004-2730000003088","url":null,"abstract":"<p><strong>Objective: </strong>Zinc transporter 8 autoantibodies (ZnT8A) have been poorly studied in non-Caucasian individuals. We aimed to investigate the prevalence of ZnT8 autoantibodies in patients with T1D and their first degree relatives (FDR) from a multiethnic population, as well as its relation with the insulin (INS) or the protein tyrosine phosphatase non-receptor 22 (PTPN22) gene polymorphisms.</p><p><strong>Subjects and methods: </strong>ZnT8A were analyzed in sera from T1D patients (n = 72, mean age of 30.3 ± 11.4 years) of variable duration (15.7 ± 11.8 years) and their FDR (n = 78, mean age of 18.3 ± 9.1 years) by a triple mix Radioligand Binding Assay (RBA) for the ZnT8 autoantibody (ZnT8-RWQ) variants. SNP (single nucleotide polymorphism) for INS and PTPN22 were genotyped.</p><p><strong>Results: </strong>The prevalence of ZnT8A was higher in T1D patients than FDR, for ZnT8TripleA (24% vs. 4%,p = 0.001), ZnT8RA (24% vs. 4%, p < 0.001) and ZnT8QA (15% vs. 3%, p = 0.004). All FDR with ZnT8A (n = 3) had at least another positive antibody. Heterozygosis for PTPN22 was associated with a higher frequency of ZnT8TripleA (p = 0.039) and ZnT8RA (p = 0.038).</p><p><strong>Conclusions: </strong>ZnT8A is observed in non-Caucasian patients with T1D, even years after the disease onset, as well as in their FDR. In those, there was an overlap between ZnT8A and other T1D antibodies. ZnT8A was associated with PTPN22 polymorphisms. Further longitudinal studies are necessary to elucidate the importance of these findings in the natural history of T1D patients with multiethnic background.</p>","PeriodicalId":8395,"journal":{"name":"Arquivos brasileiros de endocrinologia e metabologia","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2014-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1590/0004-2730000003088","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32793767","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 8
The role of imaging in congenital adrenal hyperplasia. 影像学在先天性肾上腺增生中的作用。
Pub Date : 2014-10-01 DOI: 10.1590/0004-2730000003371
Sara Reis Teixeira, Paula Condé Lamparelli Elias, Marco Túlio Soares Andrade, Andrea Farias Melo, Jorge Elias Junior

Congenital adrenal hyperplasia (CAH) is an autossomic recessive disorder caused by impaired steroidogenesis. Patients with CAH may present adrenal insufficiency with or without salt-wasting, as well as various degrees of virilization and fertility impairment, carrying a high incidence of testicular adrenal rest tumors and increased incidence of adrenal tumors. The diagnosis of CAH is made based on the adrenocortical profile hormonal evaluation and genotyping, in selected cases. Follow-up is mainly based on hormonal and clinical evaluation. Utility of imaging in this clinical setting may be helpful for the diagnosis, management, and follow-up of the patients, although recommendations according to most guidelines are weak when present. Thus, the authors aimed to conduct a narrative synthesis of how imaging can help in the management of patients with CAH, especially focused on genitography, ultrasonography, computed tomography, and magnetic resonance imaging.

先天性肾上腺增生症(CAH)是一种常染色体隐性疾病,由类固醇生成受损引起。CAH患者可表现为伴或不伴盐耗的肾上腺功能不全,以及不同程度的男性化和生育功能障碍,睾丸肾上腺休息瘤发病率高,肾上腺肿瘤发病率增高。在选定的病例中,CAH的诊断是基于肾上腺皮质谱、激素评估和基因分型。随访主要基于激素和临床评价。在这种临床环境中,影像学的应用可能有助于患者的诊断、管理和随访,尽管根据大多数指南的建议在存在时是弱的。因此,作者的目的是对影像如何帮助CAH患者的管理进行叙述综合,特别是侧重于生殖器造影,超声检查,计算机断层扫描和磁共振成像。
{"title":"The role of imaging in congenital adrenal hyperplasia.","authors":"Sara Reis Teixeira,&nbsp;Paula Condé Lamparelli Elias,&nbsp;Marco Túlio Soares Andrade,&nbsp;Andrea Farias Melo,&nbsp;Jorge Elias Junior","doi":"10.1590/0004-2730000003371","DOIUrl":"https://doi.org/10.1590/0004-2730000003371","url":null,"abstract":"<p><p>Congenital adrenal hyperplasia (CAH) is an autossomic recessive disorder caused by impaired steroidogenesis. Patients with CAH may present adrenal insufficiency with or without salt-wasting, as well as various degrees of virilization and fertility impairment, carrying a high incidence of testicular adrenal rest tumors and increased incidence of adrenal tumors. The diagnosis of CAH is made based on the adrenocortical profile hormonal evaluation and genotyping, in selected cases. Follow-up is mainly based on hormonal and clinical evaluation. Utility of imaging in this clinical setting may be helpful for the diagnosis, management, and follow-up of the patients, although recommendations according to most guidelines are weak when present. Thus, the authors aimed to conduct a narrative synthesis of how imaging can help in the management of patients with CAH, especially focused on genitography, ultrasonography, computed tomography, and magnetic resonance imaging.</p>","PeriodicalId":8395,"journal":{"name":"Arquivos brasileiros de endocrinologia e metabologia","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2014-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1590/0004-2730000003371","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32794896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 10
Is it necessary to increase the dose of levothyroxine in patients with hypothyroidism who use omeprazole? 使用奥美拉唑的甲状腺功能减退患者是否需要增加左旋甲状腺素的剂量?
Pub Date : 2014-10-01 DOI: 10.1590/0004-2730000002997
Raquel de Carvalho Abi-Abib, Mário Vaisman

Objective: It is believed that gastric pH interferes in levothyroxine absorption. Omeprazole, which acts by blocking the secretion of gastric acid, might interfere in hypothyroidism control in patients using levothyroxine and this effect could be dose dependent. The present study aimed to investigate this possibility.

Subjects and methods: Twenty-one patients with primary hypothyroidism who had been using a stabilized levothyroxine dosage for at least one year were selected and randomly assigned to take omeprazole at the dosage of 40 mg or 20 mg per day. The mean levels of thyroid-stimulating hormone (TSH) before and 3 months after omeprazole usage were compared in the entire sample and in each group.

Results: Ten patients concluded the entire treatment protocol in the 20 mg group and nine patients in the 40 mg group. There was no significant difference in TSH levels before and 3 months after omeprazole treatment in the entire patient sample (median levels: 2.28 vs. 2.30 mU/L, respectively: p = 0.56). Analysis of each subgroup (20 and 40 mg) showed no significant variation in TSH levels before and 3 months after omeprazole treatment (median levels: 2.24 vs. 2.42 mU/L, p = 0.62, and 2.28 vs. 2.30 mU/L, p = 0.82, respectively). No significant difference in the absolute (p = 0.93) or relative (p = 0.87) delta were observed between the two subgroups.

Conclusion: Omeprazole in the dosage of 20 or 40 mg/day does not interfere in a clinically relevant manner in the treatment of patients with hypothyroidism that was previously under control.

目的:认为胃pH干扰左甲状腺素的吸收。奥美拉唑通过阻断胃酸分泌起作用,可能干扰左甲状腺素患者甲状腺功能减退的控制,且这种影响可能是剂量依赖性的。本研究旨在探讨这种可能性。研究对象和方法:选择21例使用稳定左甲状腺素剂量至少1年的原发性甲状腺功能减退患者,随机分配服用奥美拉唑,剂量为40mg / d或20mg / d。比较奥美拉唑用药前和用药后3个月全组和各组的平均促甲状腺激素(TSH)水平。结果:20mg组10例患者完成整个治疗方案,40mg组9例患者完成整个治疗方案。在整个患者样本中,奥美拉唑治疗前和治疗后3个月的TSH水平无显著差异(中位水平分别为2.28 vs 2.30 mU/L: p = 0.56)。各亚组(20和40 mg)分析显示,奥美拉唑治疗前和治疗后3个月TSH水平无显著变化(中位水平分别为2.24 vs 2.42 mU/L, p = 0.62, 2.28 vs 2.30 mU/L, p = 0.82)。两亚组间δ绝对值(p = 0.93)和δ相对值(p = 0.87)均无显著差异。结论:奥美拉唑在20或40 mg/天的剂量下对先前控制的甲状腺功能减退患者的治疗没有临床相关的影响。
{"title":"Is it necessary to increase the dose of levothyroxine in patients with hypothyroidism who use omeprazole?","authors":"Raquel de Carvalho Abi-Abib,&nbsp;Mário Vaisman","doi":"10.1590/0004-2730000002997","DOIUrl":"https://doi.org/10.1590/0004-2730000002997","url":null,"abstract":"<p><strong>Objective: </strong>It is believed that gastric pH interferes in levothyroxine absorption. Omeprazole, which acts by blocking the secretion of gastric acid, might interfere in hypothyroidism control in patients using levothyroxine and this effect could be dose dependent. The present study aimed to investigate this possibility.</p><p><strong>Subjects and methods: </strong>Twenty-one patients with primary hypothyroidism who had been using a stabilized levothyroxine dosage for at least one year were selected and randomly assigned to take omeprazole at the dosage of 40 mg or 20 mg per day. The mean levels of thyroid-stimulating hormone (TSH) before and 3 months after omeprazole usage were compared in the entire sample and in each group.</p><p><strong>Results: </strong>Ten patients concluded the entire treatment protocol in the 20 mg group and nine patients in the 40 mg group. There was no significant difference in TSH levels before and 3 months after omeprazole treatment in the entire patient sample (median levels: 2.28 vs. 2.30 mU/L, respectively: p = 0.56). Analysis of each subgroup (20 and 40 mg) showed no significant variation in TSH levels before and 3 months after omeprazole treatment (median levels: 2.24 vs. 2.42 mU/L, p = 0.62, and 2.28 vs. 2.30 mU/L, p = 0.82, respectively). No significant difference in the absolute (p = 0.93) or relative (p = 0.87) delta were observed between the two subgroups.</p><p><strong>Conclusion: </strong>Omeprazole in the dosage of 20 or 40 mg/day does not interfere in a clinically relevant manner in the treatment of patients with hypothyroidism that was previously under control.</p>","PeriodicalId":8395,"journal":{"name":"Arquivos brasileiros de endocrinologia e metabologia","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2014-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1590/0004-2730000002997","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32793766","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 11
Diagnosis, treatment, and follow-up of medullary thyroid carcinoma: recommendations by the Thyroid Department of the Brazilian Society of Endocrinology and Metabolism. 甲状腺髓样癌的诊断、治疗和随访:巴西内分泌与代谢学会甲状腺科的建议
Pub Date : 2014-10-01 DOI: 10.1590/0004-2730000003427
Ana Luiza Maia, Debora R Siqueira, Marco A V Kulcsar, Alfio J Tincani, Glaucia M F S Mazeto, Lea M Z Maciel
INTRODUCTION Medullary thyroid carcinoma (MTC) originates in the thyroid parafollicular cells and represents 3-4% of the malignant neoplasms that affect this gland. Approximately 25% of these cases are hereditary due to activating mutations in the REarranged during Transfection (RET) proto-oncogene. The course of MTC is indolent, and survival rates depend on the tumor stage at diagnosis. The present article describes clinical evidence-based guidelines for the diagnosis, treatment, and follow-up of MTC. OBJECTIVE The aim of the consensus described herein, which was elaborated by Brazilian experts and sponsored by the Thyroid Department of the Brazilian Society of Endocrinology and Metabolism, was to discuss the diagnosis, treatment, and follow-up of individuals with MTC in accordance with the latest evidence reported in the literature. MATERIALS AND METHODS After clinical questions were elaborated, the available literature was initially surveyed for evidence in the MedLine-PubMed database, followed by the Embase and Scientific Electronic Library Online/Latin American and Caribbean Health Science Literature (SciELO/Lilacs) databases. The strength of evidence was assessed according to the Oxford classification of evidence levels, which is based on study design, and the best evidence available for each question was selected. RESULTS Eleven questions corresponded to MTC diagnosis, 8 corresponded to its surgical treatment, and 13 corresponded to follow-up, for a total of 32 recommendations. The present article discusses the clinical and molecular diagnosis, initial surgical treatment, and postoperative management of MTC, as well as the therapeutic options for metastatic disease. CONCLUSIONS MTC should be suspected in individuals who present with thyroid nodules and family histories of MTC, associations with pheochromocytoma and hyperparathyroidism, and/or typical phenotypic characteristics such as ganglioneuromatosis and Marfanoid habitus. Fine-needle nodule aspiration, serum calcitonin measurements, and anatomical-pathological examinations are useful for diagnostic confirmation. Surgery represents the only curative therapeutic strategy. The therapeutic options for metastatic disease remain limited and are restricted to disease control. Judicious postoperative assessments that focus on the identification of residual or recurrent disease are of paramount importance when defining the follow-up and later therapeutic management strategies.
简介:甲状腺髓样癌(MTC)起源于甲状腺滤泡旁细胞,占甲状腺恶性肿瘤的3-4%。大约25%的病例是遗传性的,由于转染(RET)原癌基因重排时激活突变。MTC病程缓慢,生存率取决于诊断时的肿瘤分期。本文介绍临床循证指南的诊断,治疗和随访的MTC。目的:本文所述的共识是由巴西专家详细阐述并由巴西内分泌与代谢学会甲状腺科赞助的,目的是根据文献中报道的最新证据讨论MTC患者的诊断、治疗和随访。材料和方法:在详细阐述临床问题后,首先在MedLine-PubMed数据库中调查现有文献,然后在Embase和科学电子图书馆在线/拉丁美洲和加勒比卫生科学文献(SciELO/Lilacs)数据库中调查证据。根据基于研究设计的牛津证据水平分类来评估证据的强度,并为每个问题选择最佳证据。结果:与MTC诊断相关的问题有11个,与手术治疗相关的问题有8个,与随访相关的问题有13个,共计32条建议。本文讨论了MTC的临床和分子诊断、初始手术治疗和术后管理,以及转移性疾病的治疗选择。结论:在有甲状腺结节和MTC家族史、与嗜铬细胞瘤和甲状旁腺功能亢进相关和/或典型表型特征(如神经节神经瘤病和类马氏体质)的个体中应怀疑MTC。细针结节抽吸、血清降钙素测定和解剖病理检查可用于诊断确认。手术是唯一的治疗策略。转移性疾病的治疗选择仍然有限,仅限于疾病控制。在确定随访和后期治疗管理策略时,关注残留或复发疾病的明智的术后评估至关重要。
{"title":"Diagnosis, treatment, and follow-up of medullary thyroid carcinoma: recommendations by the Thyroid Department of the Brazilian Society of Endocrinology and Metabolism.","authors":"Ana Luiza Maia,&nbsp;Debora R Siqueira,&nbsp;Marco A V Kulcsar,&nbsp;Alfio J Tincani,&nbsp;Glaucia M F S Mazeto,&nbsp;Lea M Z Maciel","doi":"10.1590/0004-2730000003427","DOIUrl":"https://doi.org/10.1590/0004-2730000003427","url":null,"abstract":"INTRODUCTION Medullary thyroid carcinoma (MTC) originates in the thyroid parafollicular cells and represents 3-4% of the malignant neoplasms that affect this gland. Approximately 25% of these cases are hereditary due to activating mutations in the REarranged during Transfection (RET) proto-oncogene. The course of MTC is indolent, and survival rates depend on the tumor stage at diagnosis. The present article describes clinical evidence-based guidelines for the diagnosis, treatment, and follow-up of MTC. OBJECTIVE The aim of the consensus described herein, which was elaborated by Brazilian experts and sponsored by the Thyroid Department of the Brazilian Society of Endocrinology and Metabolism, was to discuss the diagnosis, treatment, and follow-up of individuals with MTC in accordance with the latest evidence reported in the literature. MATERIALS AND METHODS After clinical questions were elaborated, the available literature was initially surveyed for evidence in the MedLine-PubMed database, followed by the Embase and Scientific Electronic Library Online/Latin American and Caribbean Health Science Literature (SciELO/Lilacs) databases. The strength of evidence was assessed according to the Oxford classification of evidence levels, which is based on study design, and the best evidence available for each question was selected. RESULTS Eleven questions corresponded to MTC diagnosis, 8 corresponded to its surgical treatment, and 13 corresponded to follow-up, for a total of 32 recommendations. The present article discusses the clinical and molecular diagnosis, initial surgical treatment, and postoperative management of MTC, as well as the therapeutic options for metastatic disease. CONCLUSIONS MTC should be suspected in individuals who present with thyroid nodules and family histories of MTC, associations with pheochromocytoma and hyperparathyroidism, and/or typical phenotypic characteristics such as ganglioneuromatosis and Marfanoid habitus. Fine-needle nodule aspiration, serum calcitonin measurements, and anatomical-pathological examinations are useful for diagnostic confirmation. Surgery represents the only curative therapeutic strategy. The therapeutic options for metastatic disease remain limited and are restricted to disease control. Judicious postoperative assessments that focus on the identification of residual or recurrent disease are of paramount importance when defining the follow-up and later therapeutic management strategies.","PeriodicalId":8395,"journal":{"name":"Arquivos brasileiros de endocrinologia e metabologia","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2014-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1590/0004-2730000003427","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32794895","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 32
Ten-year evaluation of a Neonatal Screening Program for congenital adrenal hyperplasia. 先天性肾上腺增生新生儿筛查项目的十年评价。
Pub Date : 2014-10-01 DOI: 10.1590/0004-2730000003310
Marilza Leal Nascimento, Anísia Nhelety Baptista Cristiano, Tatiane de Campos, Masanao Ohira, Edson Cechinel, Genoir Simoni, Juliana van de Sande Lee, Rose Marie Muller Linhares, Paulo Cesar Alves da Silva

Objective: Evaluate the Neonatal Screening Program (NSP) for congenital adrenal hyperplasia (CAH) of the Department of Health of the State of Santa Catarina (Secretaria de Estado da Saúde de Santa Catarina, SES/SC), and provide information to improve the program.

Subjects and methods: Descriptive, retrospective study of 748,395 children screened between January 2001 and December 2010. We analyzed the coverage of the NSP-SES/SC prevalence of CAH, child's age when the first sample for 17-hydroxyprogesterone (17OHP) measurement was collected, levels of 17OHP, mean age at treatment onset and main clinical manifestations.

Results: The NSP-SES/SC covered 89% of the live newborns in the State. It diagnosed 50 cases of CAH, yielding an incidence of 1:14,967. Mean age at collection of the first sample was 7.3 days and mean level of 17OHP was 152.9 ng/mL. The most frequent manifestations were virilized genitalia with nonpalpable gonads, clitoromegaly and genital hyperpigmentation. In three girls, the genre established at birth was incorrect. The salt-wasting form was present in 74% of the cases. There was no occurrence of shock or death. Mean age at treatment onset in the salt-wasting form was 17.4 days compared with 54.9 days in those without the salt-wasting form of the disease. All children were treated with hydrocortisone, and those with salt-wasting CAH were also treated with fludrocortisone.

Conclusions: The incidence of CAH was 1 case to 14,967 live newborns. Collection of the first sample occurred outside the recommended time, resulting in delays in treatment onset.

目的:评价圣卡塔琳娜州卫生部(secretariat de Estado da Saúde de Santa Catarina, SES/SC)先天性肾上腺增生症(CAH)新生儿筛查方案(NSP),并为改进该方案提供信息。研究对象和方法:对2001年1月至2010年12月筛查的748,395名儿童进行描述性、回顾性研究。我们分析了NSP-SES/SC CAH患病率的覆盖率、首次采集17-羟孕酮(17OHP)样本时的儿童年龄、17OHP水平、治疗开始时的平均年龄和主要临床表现。结果:NSP-SES/SC覆盖了该州89%的活产新生儿。诊断出50例CAH,发病率为1:14,967。第一次采集时平均年龄7.3 d, 17OHP平均水平为152.9 ng/mL。最常见的表现是生殖器男性化,性腺摸不到,阴蒂肥大和生殖器色素沉着。在三个女孩身上,出生时确立的体裁是不正确的。在74%的病例中存在盐消耗形式。没有发生休克或死亡。盐损耗型患者的平均发病年龄为17.4天,而无盐损耗型患者的平均发病年龄为54.9天。所有的儿童都用氢化可的松治疗,那些盐消耗性CAH也用氟化可的松治疗。结论:14967例活产儿中CAH发生率为1例。第一次样本采集时间超出了建议时间,导致治疗开始延迟。
{"title":"Ten-year evaluation of a Neonatal Screening Program for congenital adrenal hyperplasia.","authors":"Marilza Leal Nascimento,&nbsp;Anísia Nhelety Baptista Cristiano,&nbsp;Tatiane de Campos,&nbsp;Masanao Ohira,&nbsp;Edson Cechinel,&nbsp;Genoir Simoni,&nbsp;Juliana van de Sande Lee,&nbsp;Rose Marie Muller Linhares,&nbsp;Paulo Cesar Alves da Silva","doi":"10.1590/0004-2730000003310","DOIUrl":"https://doi.org/10.1590/0004-2730000003310","url":null,"abstract":"<p><strong>Objective: </strong>Evaluate the Neonatal Screening Program (NSP) for congenital adrenal hyperplasia (CAH) of the Department of Health of the State of Santa Catarina (Secretaria de Estado da Saúde de Santa Catarina, SES/SC), and provide information to improve the program.</p><p><strong>Subjects and methods: </strong>Descriptive, retrospective study of 748,395 children screened between January 2001 and December 2010. We analyzed the coverage of the NSP-SES/SC prevalence of CAH, child's age when the first sample for 17-hydroxyprogesterone (17OHP) measurement was collected, levels of 17OHP, mean age at treatment onset and main clinical manifestations.</p><p><strong>Results: </strong>The NSP-SES/SC covered 89% of the live newborns in the State. It diagnosed 50 cases of CAH, yielding an incidence of 1:14,967. Mean age at collection of the first sample was 7.3 days and mean level of 17OHP was 152.9 ng/mL. The most frequent manifestations were virilized genitalia with nonpalpable gonads, clitoromegaly and genital hyperpigmentation. In three girls, the genre established at birth was incorrect. The salt-wasting form was present in 74% of the cases. There was no occurrence of shock or death. Mean age at treatment onset in the salt-wasting form was 17.4 days compared with 54.9 days in those without the salt-wasting form of the disease. All children were treated with hydrocortisone, and those with salt-wasting CAH were also treated with fludrocortisone.</p><p><strong>Conclusions: </strong>The incidence of CAH was 1 case to 14,967 live newborns. Collection of the first sample occurred outside the recommended time, resulting in delays in treatment onset.</p>","PeriodicalId":8395,"journal":{"name":"Arquivos brasileiros de endocrinologia e metabologia","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2014-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1590/0004-2730000003310","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32793744","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 20
Serum levels of retinol binding protein 4 in women with different levels of adiposity and glucose tolerance. 不同肥胖和糖耐量水平妇女血清视黄醇结合蛋白4的水平。
Pub Date : 2014-10-01 DOI: 10.1590/0004-2730000002431
Eleonora Beltrame Comucci, Ana Carolina Junqueira Vasques, Bruno Geloneze, Antonio Ramos Calixto, José Carlos Pareja, Marcos Antonio Tambascia

Objective: Retinol-binding protein 4 (RBP4) is an adipokine responsible for vitamin A (retinol) transportation. Studies associated RBP4 increased levels with severity of type 2 diabetes mellitus (T2DM) and insulin resistance (IR). The study aimed to quantify RBP4 serum standards in women with a wide range of body mass index (BMI) and glucose tolerance level.

Subjects and methods: Cross-sectional study was performed with 139 women divided into three groups: Group 1 (lean-control, n = 45) and Group 2 (obese, n = 53) with normal glucose tolerance and group 3 (obese with T2DM, n = 41), called G1, G2 and G3. Were assessed clinical, biochemical, anthropometric and body composition parameters.

Results: According to data analysis, we obtained in G1 higher RBP4 levels (104.8 ± 76.8 ng/mL) when compared to G2 (87.9 ± 38 ng/mL) and G3 (72.2 ± 15.6 ng/mL) levels. Also, were found: in G1 positive correlations of RBP4 with BMI (r = 0.253), glycated hemoglobin (r = 0.378) and fasting insulin (r = 0.336); in G2 with glycated hemoglobin (r = 0.489); in G3 with glycated hemoglobin (r = 0.330), fasting glucose (r = 0.463), HOMA-IR (r = 0.481).

Conclusions: Although RBP4 have shown lower levels in diabetic and obese, a strong correlation with HOMA-IR index highlights that, in our study, there is growing IR when there is an increasing in RBP4 levels.

目的:视黄醇结合蛋白4 (RBP4)是一种参与维生素A(视黄醇)运输的脂肪因子。研究表明RBP4水平升高与2型糖尿病(T2DM)和胰岛素抵抗(IR)的严重程度有关。该研究旨在量化具有广泛体重指数(BMI)和葡萄糖耐量水平的女性的RBP4血清标准。研究对象和方法:139名女性进行横断面研究,分为三组:1组(瘦对照,n = 45), 2组(肥胖,n = 53),糖耐量正常,3组(肥胖合并T2DM, n = 41),分别称为G1、G2和G3。评估临床、生化、人体测量和身体成分参数。结果:根据数据分析,G1组RBP4水平(104.8±76.8 ng/mL)高于G2组(87.9±38 ng/mL)和G3组(72.2±15.6 ng/mL)。G1期RBP4与BMI (r = 0.253)、糖化血红蛋白(r = 0.378)、空腹胰岛素(r = 0.336)呈正相关;G2组糖化血红蛋白(r = 0.489);G3组糖化血红蛋白(r = 0.330)、空腹血糖(r = 0.463)、HOMA-IR (r = 0.481)。结论:虽然RBP4在糖尿病和肥胖中水平较低,但与HOMA-IR指数的强相关性表明,在我们的研究中,RBP4水平升高时,IR也随之升高。
{"title":"Serum levels of retinol binding protein 4 in women with different levels of adiposity and glucose tolerance.","authors":"Eleonora Beltrame Comucci,&nbsp;Ana Carolina Junqueira Vasques,&nbsp;Bruno Geloneze,&nbsp;Antonio Ramos Calixto,&nbsp;José Carlos Pareja,&nbsp;Marcos Antonio Tambascia","doi":"10.1590/0004-2730000002431","DOIUrl":"https://doi.org/10.1590/0004-2730000002431","url":null,"abstract":"<p><strong>Objective: </strong>Retinol-binding protein 4 (RBP4) is an adipokine responsible for vitamin A (retinol) transportation. Studies associated RBP4 increased levels with severity of type 2 diabetes mellitus (T2DM) and insulin resistance (IR). The study aimed to quantify RBP4 serum standards in women with a wide range of body mass index (BMI) and glucose tolerance level.</p><p><strong>Subjects and methods: </strong>Cross-sectional study was performed with 139 women divided into three groups: Group 1 (lean-control, n = 45) and Group 2 (obese, n = 53) with normal glucose tolerance and group 3 (obese with T2DM, n = 41), called G1, G2 and G3. Were assessed clinical, biochemical, anthropometric and body composition parameters.</p><p><strong>Results: </strong>According to data analysis, we obtained in G1 higher RBP4 levels (104.8 ± 76.8 ng/mL) when compared to G2 (87.9 ± 38 ng/mL) and G3 (72.2 ± 15.6 ng/mL) levels. Also, were found: in G1 positive correlations of RBP4 with BMI (r = 0.253), glycated hemoglobin (r = 0.378) and fasting insulin (r = 0.336); in G2 with glycated hemoglobin (r = 0.489); in G3 with glycated hemoglobin (r = 0.330), fasting glucose (r = 0.463), HOMA-IR (r = 0.481).</p><p><strong>Conclusions: </strong>Although RBP4 have shown lower levels in diabetic and obese, a strong correlation with HOMA-IR index highlights that, in our study, there is growing IR when there is an increasing in RBP4 levels.</p>","PeriodicalId":8395,"journal":{"name":"Arquivos brasileiros de endocrinologia e metabologia","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2014-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1590/0004-2730000002431","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32793763","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 16
期刊
Arquivos brasileiros de endocrinologia e metabologia
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1